Found 77 articles
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
Blue Water Vaccines Inc. today issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission (“SEC”) on April 20, 2022, which included a presentation (the “WVC presentation”) delivered by the Company at the World Vaccine Congress 2022 in Washington, DC.
Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the closing of its previously announced private placement of 1,180,812 shares of common stock (or common stock equivalents in lieu thereof), that was priced at-the-market under Nasdaq rules.
Oragenics to Participate at the World Vaccine Congress Washington 2022
Oragenics, Inc. announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Blue Water Vaccines Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,180,812 shares of common stock in a private placement priced at-the-market under Nasdaq rules.
Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that Brian Price, Ph.D., Head of Technology Strategy, will deliver a presentation during the World Vaccine Congress 2022 in Washington, DC.
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.
Blue Water Vaccines Announces Closing of Initial Public Offering
Blue Water Vaccines Inc., a biopharmaceutical company developing vaccines, announced the closing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share.
Blue Water Vaccines Announces Pricing of approximate $20M Initial Public Offering
Blue Water Vaccines, Inc. announced the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
Oh, Where Vaccines Could Take Us
1/12/20222021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.
Applied DNA and CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution for Compliance with OSHA Mandate for COVID-19 Vaccination and Testing
Applied DNA Sciences, Inc. stand ready to help large employers prepare for compliance with the federally directed OSHA Emergency Temporary Standard (“ETS”) with a turnkey and cost-effective integrated offering to efficiently track employee COVID-19 vaccination status
Desmopressin Acetate Market: Rising prevalence of diabetes to drive the market
The global desmopressin acetate market is witnessing a continuously changing market dynamics.
Blue Water Vaccines, Inc. Files Registration Statement for Initial Public Offering of Common Stock
Blue Water Vaccines, Inc. a biopharmaceutical company developing vaccines, announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Blue Water Vaccines, Inc. Announces Exclusive Rights to Patent Awarded to Oxford University Innovation Limited for the Development of a Universal Influenza Vaccine
Blue Water Vaccines, Inc. a biopharmaceutical company developing vaccines, announced that it has exclusive rights to a United States patent recently awarded to its licensor, Oxford University Innovation Limited.
Blue Water Vaccines Announces the Appointment of Ronald R. Cobb as the Head of Science and Discovery
Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery.
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
UroGen Pharma Ltd. today announced that it expects net product revenue from Jelmyto sales for the second quarter ended June 30, 2021
Blue Water Vaccines Announces Exclusive, Global License Agreement of Novel Versatile Vaccine Platform from Cincinnati Children's Hospital Medical Center
Blue Water Vaccines, Inc., a biopharmaceutical company, announced that it has licensed a novel virus-like particle vaccine platform from Cincinnati Children's Hospital Medical Center.
Blue Water Vaccines Announces the Appointments of Former Congressman Theodore S. Yoho as the Head of Business Development and Manufacturing Expert Andrew D. Skibo as the Global Head of Biologics Operations
Blue Water Vaccines, Inc., a biopharmaceutical company, announced that it has engaged the services of former Congressman Theodore Scott Yoho, as the Head of Business Development and veteran vaccine manufacturing specialist Andrew D. Skibo as Global Head of Biologics Operations.
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
UroGen Pharma today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Company’s recent developments.
Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics, Forming A Publicly Listed Company To Address Unmet Needs Of Men And Women Through Development Of Androgen And Metabolic Therapies
Existing Clarus investors, led by H. I. G. Capital, will invest an additional $25 million in support of the company Transaction will accelerate commercialization of JATENZO®, the market-leading oral testosterone replacement therapy, and fund expansion of the company's pipeline of androgen and metabolic therapies for men and women, including orphan indications Clarus Therapeutics shareholders and Blue Water Acquisition Corp. shareholders will hold shares in Clarus Therapeutics